You are here: Industry Insights > Precigen

News List

First Patient Dosed for AdenoVerse Immunotherapy for Recurrent Respiratory Papillomatosis americanpharmaceuticalreview
March 30, 2021
Precigen announced the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP).
Precigen Receives Orphan Drug Designation for PRGN-AdenoVerse™ Immunotherapy for Respiratory Papillomatosis americanpharmaceuticalreview
March 24, 2021
Precigen announced the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy for recurrent respiratory papillomatosis (RRP).
Precigen Announces IND to Begin Study of AdenoVerse Immunotherapy for RRP americanpharmaceuticalreview
January 13, 2021
Precigen announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase I clinical trial of Precigen's PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) ...
Precigen Announces First Patient Dosed in PRGN-3006 UltraCAR-T™ Study americanpharmaceuticalreview
June 28, 2019
Precigen announced that the first patient has been dosed with PRGN-3006, a first-in-class investigational therapy using Precigen's non-viral UltraCAR-T™ therapeutic platform.
Precigen Opens Cell Therapy Mfg. Facility in MD contractpharma
April 28, 2019
Precigen, Inc., a wholly-owned subsidiary of Intrexon Corp. and a clinical stage biopharmaceutical company specializing in the development of gene and cellular therapies has opened its new manufacturing facility in Germantown, MD.
Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland firstwordpharma
April 26, 2019
GERMANTOWN, Md., April 25, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and ...